Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00154635
Recruitment Status : Unknown
Verified September 2005 by National Taiwan University Hospital.
Recruitment status was:  Not yet recruiting
First Posted : September 12, 2005
Last Update Posted : September 12, 2005
Sponsor:
Collaborators:
Development Center for Biotechnology, Taiwan
Taipei Veterans General Hospital, Taiwan
Program Office, National Science & Technology, Biotechnology & Pharmaceuticals
Information provided by:
National Taiwan University Hospital

Brief Summary:
A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer’s Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.

Condition or disease Intervention/treatment Phase
Dementia, Alzheimer Type Drug: DCB-AD1 Phase 2

Detailed Description:

The growing number of patients with dementia has become a great concern of many aging societies. Up to this moment no treatment can stop Alzheimer’s dementia (AD), thus, developing new treatments are still mandatory. In this study we will investigate a new drug DCB-AD1, an herbal medicine derived from root of Fo-ti. Historically the Chinese used the Fo-ti root for its rejuvenating properties to treat premature aging, weakness and so on. In DCB (Development Center of Biotechnology)’s preliminary studies using human neuroblastoma cell, SK-N-SH, Fo-ti water extracts exhibited high potential in preventing A-beta and hydrogen peroxide-induced cell death. From two different AD animal models, DCB have observed neuroprotection effects of Fo-ti using water maze and hole-board exploration tests, Though the pharmacological effect of Fo-ti has yet been clarified, its protective effect may result from radical scavenging activities, anti-inflammatory effect or anti-peroxidation. We intend to investigate DCB-AD1 on its cognitive and neurophysiological effects on Alzheimer disease through a randomized, double-blind, placebo-controlled therapeutic trial for 24 weeks. We will complete 80 eligible cases for analysis in this clinical trial with 40 in each investigation site. The estimated drop-out rate is around 25~30 %. Patients are eligible if they fulfill criteria for a diagnosis of probable AD of NINCDS-ADRDA. We will include patients with Mini-Mental State Examination scores of 12~24 and Clinical Dementia Rating 1 or 2. Patients will be allowed to take cholinesterase inhibitors, donepezil, rivastigmine, galantamine or memantine if the dose has been unchanged for the last 3 months before the study entry and remains stable during the 24-week study period.

As for the outcome measures, the primary end point will be the score changes of ADAS-Cog at the end of treatment from the baseline. Secondary end points include CIBIC-PLUS, IADL, Behav-AD, MMSE and CDR.

The statistic analysis will be on both intention-to-treat and completed cases. Because of the limitation of the sample size we would expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We will valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease
Study Start Date : September 2005

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. ADAS-Cog

Secondary Outcome Measures :
  1. CIBIC-PLUS
  2. IADL
  3. Behav-AD
  4. MMSE
  5. CDR


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or post menopausal female patients aged ≧50 years old;
  2. The informed consent must be signed by the patient and co-signed by their proxy or principal caregivers before undergoing any study procedures;
  3. Probable Alzheimer’s disease based on the National Institute of Neurological and Communicative Disorders and Alzheimer’s dementia and related disorder (NINCDS-ADRDA)
  4. Patients with Mini-Mental State Examination (MMSE) scores of 12~24
  5. Patients with Clinical Dementia Rating (CDR)in mild (CDR = 1) and moderate (CDR = 2) AD
  6. Cranial computed tomography (CT) or brain magnetic resonance imaging (MRI) must be within the past 12 months;
  7. Patients must be able to complete baseline assessments;
  8. An eligible principal caregiver must be able to accompany the patient to all scheduled visits;
  9. Patients currently taking ChEIs such as donepezil, rivastigmine, or galantamine are allowed if the dose has been unchanged for the last 3 months before the study entry.

Exclusion Criteria:

  1. Patients with history of severe systemic disease such as coronary artery disease, myocardial infarct, progressive heart failure, chronic obstructive pulmonary disease within the past 1 year;
  2. Patients with hepatic and renal insufficiency (ALT、AST 3 times above normal range; serum creatinine 2 times above normal range), diabetic patients with poor control of blood sugar (HbA1c>8.5) at study entry;
  3. Patients with central nervous system disease other than AD such as cerebral vascular disease, Parkinson’s disease, epilepsy, traumatic brain injury, central nervous system infection, and alcoholic encephalopathy;
  4. Patients with concurrent psychosis or mood disorder (Hamilton depression scale score > 17);
  5. Patients diagnosed cancer and treated within the past two years (except for non-invasive skin cancer);
  6. Patients with general medical conditions, which may confound the results of the study, pose additional risk or preclude evaluation and assessments in this study as judged by the investigator;
  7. Patients currently treated with any prohibited medications (listed in Concomitant Treatment section) are not able to fulfill the 2 week-washout period;
  8. Participation in another study within the last 30 days;
  9. Females who are within two years of their menopause unless proved not pregnant (determined by urine test);
  10. Dementia caused by other etiology as indicated by clinically significant abnormal Vit B12, folic acid, or thyroid function tests.
  11. Patients with neurosyphilis confirmed by CSF STS/TPHA;
  12. The neuroimage CT or MRI could not be compatible with the diagnosis of probable AD as stated in the NINCDS criteria;
  13. Patients with a Hachinski score (Appendix 5) above 3 are excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00154635


Contacts
Layout table for location contacts
Contact: Ming-Jang Chiu, MD, PhD 886-968661507 mjchiu@ntumc.org

Locations
Layout table for location information
Taiwan
NTUH
Taipei, Taiwan, 100
Contact: Ming-Jang Chiu, MD, PhD    886-968661507    mjchiu@ntumc.org   
Principal Investigator: Ming-Jang Chiu, MD, PhD         
VGH
Taipei, Taiwan
Contact: Hsiu-Chih Liu, MD    886-2-28757492    hcliu@vghtpe.gov.tw   
Principal Investigator: Hsiu-Chih Liu, MD         
Sponsors and Collaborators
National Taiwan University Hospital
Development Center for Biotechnology, Taiwan
Taipei Veterans General Hospital, Taiwan
Program Office, National Science & Technology, Biotechnology & Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Ming-Jang Chiu, MD, PhD NTUH
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00154635    
Other Study ID Numbers: 931006
NTUH IRB 931006
VGH IRB 93-11-06
DCB-AD1-01-01
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: September 12, 2005
Last Verified: September 2005
Keywords provided by National Taiwan University Hospital:
Alzheimer's disease
Fo-ti
Chinese herbs
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders